Search Results - "Camara, Juan A."
-
1
MiR-93 Controls Adiposity via Inhibition of Sirt7 and Tbx3
Published in Cell reports (Cambridge) (08-09-2015)“…Conquering obesity has become a major socioeconomic challenge. Here, we show that reduced expression of the miR-25-93-106b cluster, or miR-93 alone, increases…”
Get full text
Journal Article -
2
Prostate‐Specific Membrane Antigen Targeted StarPEG Nanocarrier for Imaging and Therapy of Prostate Cancer
Published in Advanced healthcare materials (01-07-2024)“…The tumor uptake of large non‐targeted nanocarriers primarily occurs through passive extravasation, known as the enhanced permeability and retention (EPR)…”
Get full text
Journal Article -
3
Plk1 regulates contraction of postmitotic smooth muscle cells and is required for vascular homeostasis
Published in Nature medicine (01-08-2017)“…The kinase Plk1 has been studied primarily as a mitotic regulator in dividing cells, but de Cárcer et al . find that Plk1 deficiency or inhibition in mice…”
Get full text
Journal Article -
4
Precision Oncology and Systemic Targeted Therapy in Pseudomyxoma Peritonei
Published in Clinical cancer research (13-09-2024)“…Pseudomyxoma peritonei (PMP) is a rare and poorly understood malignant condition characterized by the accumulation of intra-abdominal mucin produced from…”
Get full text
Journal Article -
5
Los primeros objetos de adorno personal de la prehistoria reciente del poblado de Los Castillejos en Las Peñas de los Gitanos (Montefrío, España)
Published in Temas (Editorial Universitaria de Buenos Aires). (01-06-2018)“…En este trabajo exponemos los resultados de los análisis de los adornos del poblado de Los Castillejos en Las Peñas de los Gitanos (Montefrío, España) hallados…”
Get full text
Journal Article -
6
Phase II trial of erlotinib plus capecitabine as first-line treatment for metastatic pancreatic cancer (XELTA study)
Published in Anticancer research (01-02-2013)“…To evaluate the efficacy and safety of erlotinib plus capecitabine for metastatic pancreatic cancer. This was a multicenter, uncontrolled, phase II trial…”
Get full text
Journal Article